Pancreatic cancer is one of the most lethal types of cancer with a 5-year survival rate of ~5%. Creative Biolabs has focused on the research of finding new treatments for pancreatic cancer for many years. The pancreatic cancer cell AR42J cell line is a useful model and has been paid more and more attention in the development of new therapy for pancreatic cancer. Creative Biolabs combines a diverse range of platforms with a tenured team who are experts in engineering AR42J for pancreatic cancer cell self-destruction purposes.

Introduction of AR42J Cells

AR42J cells derive initially from a transplantable tumor of a rat exocrine pancreas. This line is tumorigenic in nude mice, and it can maintain many characteristics of pancreatic acinar cells in culture, such as calcium (Ca²⁺) signaling, the synthesis and secretion of digestive enzymes, protein expression, growth and proliferation. Therefore, AR42J cells are often used as a cell-culture model of cerulein-induced acute pancreatitis (AP) and are widely used for functional studies of exocrine pancreatic acinar cells.

Fig.1 Images of pancreatic cells AR42J before and after treatment with nicotine in the concentration of 100 μM. Green color indicates apoptotic-related phenomena; red color indicates necrotic phenomena. (Zharov, et al., 2005)

Pancreatic Cancer Cell AR42J Engineering Service at Creative Biolabs

Studies have shown that tumor lymphangiogenesis can enhance cancer immunotherapy and boost T cell immunity. Scientists at Creative Biolabs have been focused on the study of tumor lymphangiogenesis for many years. We are exploring the lymphangiogenic potentiation of immunotherapy to Turning Cancer Cells Against Themselves.

AR42J cell line is a useful model in the research of new therapy for pancreatic cancer. We have developed several different Genetic Methods, including Retrovirus, Lentivirus, Adenovirus, Adeno-associated Virus, and CRISPR-based Methods, to engineer AR42J for cancer cell self-destruction purposes.

Our strategies for engineering cancer cells for self-destruction, include but are not limited to:

• Engineering Cancer Cells with Cytokine Overexpression for Stronger T Cell Activation
• Engineering Cancer Cells with Target-specific Aptamer for Cancer Immunotherapy
• Engineering Cancer Cells With Aptamer-siRNA for Enhanced Antitumor T Cell Immunity
• Engineering Cancer Cells with Synthetic Immunomodulatory Gene Circuits for Cancer Immunotherapy
• Engineering Cancer Cells with Targeted siRNA For Cancer Immunotherapy

What's more, self-destruction assays are necessary to assess the effect of self-destruction cancer cells. Our portfolio for self-destruction assessment includes but not limited to:

• Lymphangiogenesis Analysis
• Kinetics Analysis of Overexpressed Cytokine Secretion
• Naïve T Cell Infiltration Analysis
• Frequency Analysis of Antigen-presenting cells (APCs) Subsets in the Draining Lymph Nodes (dLNs)
• T Cell Activation Analysis
• Antigen-specific T Cell Response Analysis
• Determination of the Effect of Self-destruction Cancer Cells on Preexistent Tumor

For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

1. Zharov, V.P.; et al. Nanocluster model of photothermal assay: application for high-sensitive monitoring of nicotine-induced changes in metabolism, apoptosis, and necrosis at a cellular level. Journal of Biomedical Optics. 2005, 10(4): 044011.

For Research Use Only | Not For Clinical Use